Reni Benjamin
Stock Analyst at JMP Securities
(1.55)
# 3,081
Out of 4,829 analysts
187
Total ratings
39.24%
Success rate
-13.88%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.59 | +156.11% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.75 | +166.31% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.43 | +131.37% | 9 | Mar 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $11.71 | - | 9 | Mar 18, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.17 | +327.35% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $60.85 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.72 | - | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $100.27 | +24.66% | 21 | Mar 3, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.00 | +300.00% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.32 | +203.03% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.71 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.49 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.65 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.30 | +5,320.05% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $20.45 | -51.10% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.93 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.88 | +352.18% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.09 | +360.15% | 10 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $25.26 | +58.35% | 3 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $5 | $2.00 | +150.00% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.87 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $5.58 | +43.37% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $59.75 | +0.42% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.99 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $266.57 | +18.17% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $88.10 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $233.10 | +13.69% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $1.28 | +369.15% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $13.68 | - | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.35 | +407.46% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $7.97 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.59 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $34.99 | -65.70% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.14 | - | 1 | Nov 15, 2017 |
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.59
Upside: +156.11%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.75
Upside: +166.31%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.43
Upside: +131.37%
Inhibrx Biosciences
Mar 18, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $11.71
Upside: -
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.17
Upside: +327.35%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $60.85
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.72
Upside: -
Blueprint Medicines
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $100.27
Upside: +24.66%
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.00
Upside: +300.00%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.32
Upside: +203.03%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.71
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.49
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.65
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.30
Upside: +5,320.05%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $20.45
Upside: -51.10%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.93
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.88
Upside: +352.18%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.09
Upside: +360.15%
Apr 28, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $25.26
Upside: +58.35%
Mar 18, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $2.00
Upside: +150.00%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.87
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $5.58
Upside: +43.37%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $59.75
Upside: +0.42%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.99
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $266.57
Upside: +18.17%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $88.10
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $233.10
Upside: +13.69%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $6
Current: $1.28
Upside: +369.15%
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $13.68
Upside: -
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.35
Upside: +407.46%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $7.97
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.59
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $34.99
Upside: -65.70%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.14
Upside: -